Zydus receives final approval from USFDA for Valsartan, Hydrochlorothiazide tablets

Mumbai, Mar 16 (UNI) Pharma Major, Zydus Cadila has received the final approval from the USFDA to market Valsartan and Hydrochlorothiazide Tablets USP in the strengths of 80 mg/12.5 mg, 160 mtg/12.5 mg, 160 mg/25 mg, 320 mtg/12.5 mg, and 320 mg/25 mg.
The drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad, company said in a filing with BSE.
The group now has 256 approvals and has so far filed over 350 Abbreviated New Drug Application (ANDA) since the commencement of the filing process in FY 2003-04.